Back in May, Esperion Therapeutics (ESPR) announced the FDA set two PDUFA dates in February for the company's two leading products, bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are looking to be approved to treat elevated low-density lipoprotein cholesterol "LDL-C". What is more, Esperion has roughly $302.2M in cash, cash equivalents, restricted cash, and investment securities available to sell. Back in January, the company was able to close a licensing and collaboration agreement with Daiichi Sankyo Europe (DSNKY) to commercialize bempedoic acid and bempedoic acid/ezetimibe combination